Valproate for schizophrenia (Q24247936)

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

The unit of analysis error in studies about physicians' patient care behavior

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Dropout rates in randomised antipsychotic drug trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Evidence of ten psychotic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Combined treatment of schizophrenic psychoses with haloperidol and valproate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Effect of sodium valproate on tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

The effect of sodium valproate on tardive dyskinesia--revisited.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004028.PUB2

7 January 2021